At present, tissue-based biomarkers including PD-L1 expression level, tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR) gene defect and TIL have been proved to be reliable in predicting the effectiveness of immunotherapy for NSCLC (66, 67). The gene discussed is CD274; the disease is non-small cell lung carcinoma.